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Abstract
Introduction: Basilar artery dissection is a rare occurrence, and is significantly associated with morbidity and
mortality. To the best of our knowledge, we report the first case of basilar artery dissection treated with
mesenchymal stem cells.
Case presentation: We present the case of a 17-year-old Korean man who was diagnosed with basilar artery
dissection. Infarction of the bilateral pons, midbrain and right superior cerebellum due to his basilar artery
dissection was partially recanalized by intrathecal injection of human umbilical cord blood-derived mesenchymal
stem cells. No immunosuppressants were given to our patient, and human leukocyte antigen alloantibodies were
not detected after cell therapy.
Conclusions: This case indicates that intrathecal injections of mesenchymal stem cells can be used in the
treatment of basilar artery dissection.
Introduction
Little has been reported on the clinical manifestations of
basilar artery dissections [1]. It has been suggested that
rare cells in human umbilical cord blood (hUCB) could
be partially induced to express markers of both neurons
and glia [2]. A neural stem cell-like subpopulation could
be selected and expanded in vitro by hUCB cells, which
showed a high commitment (about 30% and 40% of the
population) to neuronal and astrocytic fates, respectively
[3]. In animal models, administration of CD34+ hUCB
cells has been shown to enhance neurogenesis via angio-
genesis, resulting in the restoration of ischemic areas [4].
We identified that hUCB contained not only hemato-
poietic stem cells (HSC) but also mesenchymal stem
cells (MSC) which expressed neural makers such as
Tuj1, TrkA, glial fibrillary acidic protein (GFAP) and
cyclic nucleotide phosphodiesterases (CNPases) facilitat-
ing a therapeutic approach for neurodegenerative
diseases [5]. Therefore, we attempted to treat our
patient with basilar artery dissection by intrathecal injec-
tion of hUCB-derived MSC.
Case presentation
A 17-year-old Korean man with basilar artery dissection
was transferred to our hospital one month after onset of
symptoms. Our patient’s National Institutes of Health
(NIH) stroke scale score was 35(Table 1). His pupils
were pinpoint, his light reflex was slightly positive, and
movements of his external ocular muscle (EOM) were
paralyzed. On cranial nerve examination, our patient
showed no response to noxious pain to his motor and
sensory nerves. Our patient was in quadriplegia both
with a sagging soft palate and a negative gag reflex, and
showed a strong clonus of the deep tendon reflex (DTR)
(Table 2). Our patient was diagnosed as having a basilar
artery dissection based on clinical manifestations and
radiological findings, including computed tomography
(CT) and MRI scans and magnetic resonance angiogra-
phy (Figure 1). Because our patient showed no therapeu-
tic response after treatment with antiplatelet drugs and
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anticoagulants for one month after onset of this disease,
an alternative approach with hUCB-derived MSC was
applied to our patient. Our patient’s human leukocyte
antigen (HLA) type was A11,24, B35,61 and DR04,14.
Our patient had no history of trauma, hypertension,
diabetes mellitus, hyperlipidemia, stroke, seizure, and
smoking or drinking. hUCB-derived MSC were prepared
according to methods described previously [5]. hUCB-
derived mononuclear cells were separated and cultured
for a few days. Non-adherent HSC were discarded, and
adherent MSC were continued in culture, with two
medium changes per week. Samples of 1.2 × 107 MSC
were prepared with each unit of hUCB. Three different
units of allogeneic hUCB-derived MSC were intrathe-
cally injected into our patient on the 35th day after
onset without using immunosuppressants or antibiotics.
Surface markers for MSC injected were CD13+, CD29+,
CD31+, CD45+, CD73+, CD90+, CD105+ and CD166+;
the HLA allele types of the donors were A11,24, B35,62
and DR04,08, respectively. Treatment of patients with
hUCB-derived MSC was approved by the Korea Food
and Drug Administration (KFDA). The improvement in
our patient’s clinical symptoms, such as a positive gag
reflex and relaxation of muscle tone rigidity, was
observed from the fifth day after treatment. The volun-
tary eyeball movement of our patient was possible on
the 27th day after treatment, and the rigidity of his mus-
cle tone was reduced enough for him to sit in a wheel-
chair (Table 2). The second and third injections of
hUCB-derived MSC were performed on the 15th day
and 41st day after first treatment, respectively. The HLA
allele types of donors on these occasions were A11,24,
B27,35 and DR04,14, respectively. No other medical
treatment was performed, and the absence of new intra-
cranial lesions was confirmed by MRI scan and mag-
netic resonance angiography (Figure 1). The
Table 1 Comparison of National Institutes of Health (NIH)
stroke scale before and after first injection of human






1a Level of consciousness
(LOC)
3 0 0
1b LOC questions 2 2 2
1c LOC commands 2 0 0
2 Best gaze 2 1 1
3 Visual 3 1 0
4 Facial palsy ? 2 2
5 Motor arm Right 4 3+/- 3
Left 4 3+/- 3
6 Motor leg Right 4 4 3
Left 4 4 3
7 Limb ataxia Untestable Untestable Untestable
8 Sensory 2 1+/- 1
9 Best language 3 2 3
10 Dysarthria Untestable Untestable Untestable
11 Extinction and attention 2 2- 1
Total 35 25 20
Table 2 Comparison of neurological findings before and after first injection of human umbilical cord blood (hUCB)-
derived mesenchymal stem cells
Onset Fifth day after 15th day after 27th day after 41st day after 60th day after
Glasgow coma scale E1 VT M2 E2 VT M4 E3 VT M4 E4 VT M4 E4 VT M4 E4 VT M4
Extension hypertonic posturing 1+/1+ 1+/1+ 1+/1+ 1+/1+ 1+/1+ 1+/1+
Ankle clonus 4+/4+ 3+/3+ 3+/3+ 3+/3+ 3+/3+ 3+/3+
Muscle tone rigidity 4+/3+ 4+/3+ 4+/3+ 2+/2+ 2+/2+ 2+/2+
Deep tendon reflex 3+/3+ 4+/3+ 4+/3+ 3+/3+ 3+/3+ 3+/3+
Babinski sign (-)/(-) (-)/(-) (-)/(-) (-)/(-) (-)/(-) (-)/(-)
Nystagmus (-) (-) (-) (-) (-) (-)
External ocular muscle Gaze paralysis Gaze paralysis Gaze paralysis Gazing 60’ Gazing 60’ Gazing 60’
Pupils Pinpoint Pinpoint Pinpoint 3+/3+ 3+/3+ 3+/3+
Light response +/+ +/+ +/+ +/+ +/+ +/+
Facial palsy (central type) (+) (+) (+) (+) (+) (+)
Gag reflex (-) (-) (-) (+) (+) (+)
Soft palate sagging (-) (-) (-) (+) (+) (+)
Anarthria (+) (+) (+) (+) (+) (+)
Dysphagia (+) (+) (+) (+/-) (-) (-)
Quadriplegia (+) (+) (+) (+) (+) (+)
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improvement of clinical symptoms began to be observed
from the fifth day after intrathecal injection of hUCB-
derived MSC, and the significant changes from the 15th
day after treatment were confirmed by radiological find-
ings. These data were similar to our previous findings
that hUCB-derived MSC had high endothelial functions
[6].
Discussion
The growth factors and stem cell populations of hUCB
could enhance the neurological recovery after stroke by
stimulation of neural sprouting and proliferation of
endogenous progenitor cells in the brain [7]. It has been
proposed that the secretion of various cytokines and
growth factors by MSC might play an important role
not only in the engraftment of transplanted HSC but
also in the neural differentiation of MSC [8]. Our pre-
vious in vitro study showed that cytokines that were
known as novel neurotropic and anti-inflammatory fac-
tors such as insulin-like growth factor (IGF)-1, IGF-2,
insulin-like growth factor binding protein (IGFBP)-1,
IGFBP-2, IGFBP-5, monocyte colony stimulating factor
(M-CSF), monocyte chemoattractant protein (MCP)-1,
regulated upon activation, normal T cell expressed and
presumably secreted (RANTES), macrophage inflamma-
tory protein (MIP)-1a, interferon-inducible protein (IP)-
10 and interleukin (IL)-8 were highly detected in the
supernatant of cultured hUCB-derived MSC. However,
the serum levels of these cytokines before and after
treatment were notably not observed in our patient,
although it was hypothesized that the functional recov-
ery might be influenced by growth factors (data not
shown). It has been reported that brain injuries of ani-
mals, caused by stroke and traumatic brain injury (TBI),
recovered when hUCB cells were injected into the ani-
mal at 24 hours after occurrence of the condition [9]. A
few cases in human patients, such as one patient who
was treated 19 and half years after spinal cord injury
[10] and another patient with Buerger’s disease [11],
have been cured by transplantation of hUCB-derived
MSC. Therefore, it was suggested that the existence of
both stem cell-specific cytokines as early effectors and
the differentiated tissue-specific cytokines as later effec-
tors could improve clinical symptoms. Because these
cytokines might contribute to the rapid neural differen-
tiation of hUCB-derived MSC, their potential usage in
Figure 1 MRI scans and magnetic resonance angiographic findings before and after first injection of human umbilical cord blood
(hUCB)-derived mesenchymal stem cells (MSC). (A) Partial recanalization of the basilar artery with residual severe stenosis was shown in the
subacute infarction sites of bilateral pons, midbrain and right superior cerebellum. (B) Bilateral hypertropic olivary degeneration and further
recanalization of the basilar artery with residual irregular stenosis was shown in the subacute to chronic infarction sites. (C) Luminal irregularity at
the mid-to-distal basilar artery with residual stenosis was shown in the chronic infarction sites. (D) No intra-cranial lesion was shown in the
chronic infarction sites, and effusion size was decreased at the right mastoid.
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the treatment of human neurological disorders, such as
basilar artery dissection, were of particular interest. The
MRI scan results and magnetic resonance angiographic
findings as shown in Figure 1A were observed about
one month after onset. Even though partial recanaliza-
tion of the basilar artery was found before intrathecal
injection of hUCB-derived MSC, the magnetic resonance
angiographic data of clinical symptoms from the 15th
day after first treatment clearly show that recanalization
of the basilar artery with residual irregular stenosis had
been helped by transplantation of these stem cells.
Conclusions
In total, nine units of allogeneic hUCB-derived MSC
were injected without using immunosuppressants. Each
unit had two out of six HLA alleles mismatched to our
patient, but the formation of HLA alloantibodies was
not detected. It is therefore thought that multiple units
of hUCB-derived MSC can be safely applied by intrathe-
cal injection for the treatment of brain infarction.
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